Erik S G Stroes

List of Publications by Citations

Source: https://exaly.com/author-pdf/2181865/erik-s-g-stroes-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172 15,371 53 123 g-index

180 19,639 8 6.1 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
172	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020 , 41, 111-188	9.5	2236
171	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013 , 34, 3478-90a	9.5	1551
170	Simvastatin with or without ezetimibe in familial hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008 , 358, 1431-43	59.2	986
169	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015 , 36, 1012-22	9.5	770
168	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014 , 35, 214	9.5 6-57	614
167	Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2541-2548	15.1	398
166	Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. <i>Diabetes</i> , 2006 , 55, 480-6	0.9	379
165	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 655-66	18.1	357
164	Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 185-97	15.1	352
163	Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. <i>Diabetes</i> , 2006 , 55, 1127-32	0.9	302
162	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019 , 139, 1483-1492	16.7	288
161	A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. <i>Nature Communications</i> , 2014 , 5, 3065	17.4	269
160	Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. <i>Circulation</i> , 2003 , 107, 2944-8	16.7	264
159	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. <i>Circulation</i> , 2016 , 134, 611-24	16.7	257
158	Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2010 , 53, 2646-55	10.3	240
157	Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circulation Research, 2000, 86, 1129-	34 5.7	238
156	Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008 , 28, 1761-70	7.3	228

(2018-2019)

155	Volanesorsen and Triglyceride Levels In Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2019 , 381, 531-542	59.2	192	
154	Activation of inflammation and coagulation after infusion of C-reactive protein in humans. <i>Circulation Research</i> , 2005 , 96, 714-6	15.7	175	
153	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1780-1788	27.4	155	
152	Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. <i>European Heart Journal</i> , 2012 , 33, 1142-9	9.5	152	
151	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. <i>Journal of the American Heart Association</i> , 2019 , 8, e011662	6	150	
150	Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. <i>Journal of Applied Physiology</i> , 2008 , 104, 845-52	3.7	147	
149	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. <i>Science Advances</i> , 2015 , 1,	14.3	137	
148	Influence of folic acid on postprandial endothelial dysfunction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 185-8	9.4	132	
147	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 473-483	3.9	125	
146	Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 1236-45	9.4	121	
145	Safety and tolerability of dalcetrapib. American Journal of Cardiology, 2009, 104, 82-91	3	117	
144	Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. <i>Annals of Internal Medicine</i> , 2007 , 146, 640-8	8	116	
143	Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. <i>European Journal of Clinical Investigation</i> , 2002 , 32 Suppl 1, 9-16	4.6	109	
142	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 593-603	3.9	107	
141	Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009 , 29, 1444-53	7.3	103	
140	A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1429-3	5 ^{15.1}	103	
139	Oral treatment with improves insulin sensitivity in mice. <i>Npj Biofilms and Microbiomes</i> , 2016 , 2, 16009	8.2	101	
138	Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. <i>Journal of the American Heart Association</i> , 2018 , 7.	6	100	

137	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2150-2162	15.1	97
136	PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2017 , 38, 1584-1593	9.5	97
135	High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 1153-8	9.4	93
134	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. <i>Circulation</i> , 2020 , 142, 621-642	16.7	88
133	Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. <i>Cell Metabolism</i> , 2019 , 30, 1-2	24.6	78
132	Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1418-26	15.1	74
131	Diagnostic algorithm for familial chylomicronemia syndrome. <i>Atherosclerosis Supplements</i> , 2017 , 23, 1-7	1.7	69
130	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". <i>Atherosclerosis</i> , 2018 , 275, 265-272	3.1	69
129	Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. <i>Diabetologia</i> , 2007 , 50, 1288-93	10.3	69
128	Thresholds for Arterial Wall Inflammation Quantified by F-FDG PET Imaging: Implications for Vascular Interventional Studies. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 1198-1207	8.4	63
127	In[Vivo PET Imaging of HDL in Multiple[Atherosclerosis[Models. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 950-61	8.4	62
126	Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. <i>European Heart Journal</i> , 2019 , 40, 2775-2781	9.5	61
125	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. <i>Nature Biomedical Engineering</i> , 2018 , 2, 279-292	19	60
124	Efficacy and Safety of Alirocumab 150mg Every 4lWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	59
123	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. <i>European Heart Journal</i> , 2018 , 39, 2589-25	5 9 &	56
122	Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2008 , 51, 1081-4	10.3	55
121	Current therapies for lowering lipoprotein (a). Journal of Lipid Research, 2016, 57, 1612-8	6.3	54
120	ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. <i>European Heart Journal</i> , 2013 , 34, 286-91	9.5	54

(2021-2017)

119	Increased haematopoietic activity in patients with atherosclerosis. <i>European Heart Journal</i> , 2017 , 38, 425-432	9.5	53	
118	Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 969-975	9.4	51	
117	The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. <i>American Journal of Cardiology</i> , 2009 , 104, 32E-8E	3	49	
116	Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2481-7	15.1	47	
115	Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction?. <i>Atherosclerosis</i> , 1998 , 137 Suppl, S51-60	3.1	46	
114	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy. <i>Circulation</i> , 2020 , 142, 1996-1998	16.7	45	
113	Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 1127-1132	1.6	45	
112	Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. <i>British Journal of Pharmacology</i> , 2009 , 158, 1763-70	8.6	42	
111	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	41	
110	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. <i>Circulation Research</i> , 2020 , 126, 1346-1359	15.7	41	
109	Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 209-17		39	
108	From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. <i>Cardiovascular Research</i> , 2018 , 114, 1714-1727	9.9	39	
107	High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. <i>Journal of Lipid Research</i> , 2013 , 54, 1698-1704	6.3	37	
106	PCSK9 inhibitors in clinical practice: Delivering on the promise?. <i>Atherosclerosis</i> , 2018 , 270, 205-210	3.1	36	
105	Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. <i>Hepatology</i> , 2012 , 55, 1746-53	11.2	36	
104	Novel anti-inflammatory strategies in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2012 , 23, 532-9	4.4	35	
103	Statins and LDL-cholesterol lowering: an overview. <i>Current Medical Research and Opinion</i> , 2005 , 21 Suppl 6, S9-16	2.5	35	
102	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021 .	9.5	35	

101	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. <i>European Heart Journal</i> , 2018 , 39, 3521-3527	9.5	34
100	Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?. <i>Cardiovascular Research</i> , 2006 , 69, 341-7	9.9	34
99	Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015 , 11, 1133-40	6	32
98	Measurement of subclinical atherosclerosis: beyond risk factor assessment. <i>Current Opinion in Lipidology</i> , 2002 , 13, 595-603	4.4	30
97	Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016 , 12, 1463-70	6	30
96	Arterial and Cellular Inflammation in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1278-1285	12.7	29
95	Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. <i>Clinical Chemistry</i> , 2010 , 56, 789-98	5.5	29
94	Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease. <i>EBioMedicine</i> , 2019 , 39, 109-117	8.8	29
93	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). <i>European Heart Journal</i> , 2020 , 41, 2262-2271	9.5	28
92	Intestinal Ralstonia pickettii augments glucose intolerance in obesity. <i>PLoS ONE</i> , 2017 , 12, e0181693	3.7	28
91	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2021 , 9, 264-275	18.1	28
90	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 948-955	3.9	27
89	Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2020 , 63, 597-610	10.3	26
88	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. <i>European Heart Journal</i> , 2020 , 41, 3998-4007	9.5	26
87	CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET/CT in patients at risk for cardiovascular disease. <i>Cardiovascular Research</i> , 2018 , 114, 468-4	73 9	25
86	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016 , 39, 137-44	3.3	25
85	Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. <i>Atherosclerosis</i> , 2012 , 225, 481-5	3.1	25
84	The dedicated "Lp(a) clinic": A concept whose time has arrived?. <i>Atherosclerosis</i> , 2020 , 300, 1-9	3.1	24

(2020-2014)

83	The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. <i>PLoS ONE</i> , 2014 , 9, e86890	3.7	24
82	Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	24
81	Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 3066-75	9.4	24
80	Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1848-51	2.4	22
79	Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 115	5.7	22
78	Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. <i>Clinical Cardiology</i> , 2014 , 37, 131-9	3.3	22
77	Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018 , 41, 1328-1335	3.3	21
76	The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3143-9	3.3	20
75	PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 2571-2573	8.4	18
74	HDL does not influence the polarization of human monocytes toward an alternative phenotype. <i>International Journal of Cardiology</i> , 2014 , 172, 179-84	3.2	18
73	Magnetic Resonance Imaging-Derived Renal Oxygenation and Perfusion During Continuous, Steady-State Angiotensin-II Infusion in Healthy Humans. <i>Journal of the American Heart Association</i> , 2016 , 5, e003185	6	18
72	How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population. <i>Diabetologia</i> , 2017 , 60, 1271-1275	10.3	17
71	Inflammation-Sensitive Myosin-X Functionally Supports Leukocyte Extravasation by Cdc42-Mediated ICAM-1-Rich Endothelial Filopodia Formation. <i>Journal of Immunology</i> , 2018 , 200, 1790-	1501	17
70	C-Reactive Protein Identifies Low-Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer-Norfolk Prospective Population Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	17
69	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 365-372	3.9	16
68	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. <i>Atherosclerosis Supplements</i> , 2017 , 26, 16-24	1.7	15
67	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 297-304	3.9	15
66	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease-Free Survival, and Mortality Risk: A Mendelian Randomization Analysis. <i>JAMA Network Open</i> , 2020 , 3, e200129	10.4	14

65	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , 2020 , 311, 13-19	3.1	14
64	Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 581641	5.7	13
63	Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. <i>Marine Drugs</i> , 2019 , 17,	6	13
62	Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. <i>Clinical Genetics</i> , 2012 , 81, 24-8	4	12
61	BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. <i>Clinical Epigenetics</i> , 2020 , 12, 166	7.7	12
60	Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2020 , 383, 1242-1247	59.2	12
59	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. <i>Bioconjugate Chemistry</i> , 2020 , 31, 360-368	6.3	12
58	Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. <i>BMJ Open</i> , 2021 , 11, e045482	3	12
57	Nile Red Quantifier: a novel and quantitative tool to study lipid accumulation in patient-derived circulating monocytes using confocal microscopy. <i>Journal of Lipid Research</i> , 2017 , 58, 2210-2219	6.3	11
56	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 119-127	6.4	11
55	Carriers of loss-of-function mutations in EXT display impaired pancreatic beta-cell reserve due to smaller pancreas volume. <i>PLoS ONE</i> , 2014 , 9, e115662	3.7	11
54	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2021 ,	9.5	11
53	HDL infusion for the management of atherosclerosis: current developments and new directions. <i>Current Opinion in Lipidology</i> , 2016 , 27, 592-596	4.4	10
52	Characterization of immune cell, endothelial, and renal responses upon experimental human endotoxemia. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018 , 89, 39-46	1.7	10
51	Gene-based therapy in lipid management: the winding road from promise to practice. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 483-493	5.9	9
50	Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 355-361	2.5	9
49	Adrenal Function in females with low plasma HDL-C due to mutations in ABCA1 and LCAT. <i>PLoS ONE</i> , 2014 , 9, e90967	3.7	9
48	Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?. <i>Cardiovascular Research</i> , 1998 , 39, 543-9	9.9	9

(2018-2020)

47	Netrin-1 and the Grade of Atherosclerosis Are Inversely Correlated in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 462-472	9.4	9	
46	Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 2038-2048	9.4	9	
45	Marked plaque regression in homozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021 , 327, 13	-137.1	9	
44	Dynamic magnetic resonance measurements of calf muscle oxygenation and energy metabolism in peripheral artery disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020 , 51, 98-107	5.6	9	
43	Increasing the Spatial Resolution of 3T Carotid MRI Has No Beneficial Effect for Plaque Component Measurement Reproducibility. <i>PLoS ONE</i> , 2015 , 10, e0130878	3.7	8	
42	Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy. <i>Stroke</i> , 2020 , 51, 2972-2982	6.7	8	
41	Impact of cholesterol on proinflammatory monocyte production by the bone marrow. <i>European Heart Journal</i> , 2021 , 42, 4309-4320	9.5	8	
40	Lipid Measures and Cardiovascular Disease Prediction. <i>Disease Markers</i> , 2009 , 26, 209-216	3.2	7	
39	Comparison of in vivo carotid 3.0-T magnetic resonance to B-mode ultrasound imaging and histology in a porcine model. <i>JACC: Cardiovascular Imaging</i> , 2009 , 2, 744-50	8.4	7	
38	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study <i>Atherosclerosis</i> , 2021 , 341, 43-4	193.1	7	
37	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 875-883	3.9	7	
36	Impact of the B Cell Growth Factor APRIL on the Qualitative and Immunological Characteristics of Atherosclerotic Plaques. <i>PLoS ONE</i> , 2016 , 11, e0164690	3.7	7	
35	Lipoprotein(a): An underestimated inflammatory mastermind. Atherosclerosis, 2022, 349, 101-109	3.1	7	
34	The maturation of a Reural-hematopoieticRinflammatory axis in cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2017 , 28, 507-512	4.4	6	
33	Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012. <i>Future Lipidology</i> , 2007 , 2, 387-393		6	
32	Finding very high lipoprotein(a): the need for routine assessment. European Journal of Preventive Cardiology, 2021 ,	3.9	6	
31	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320942996	3.9	5	
30	Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with F-DPA-714 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1956-1963	8.8	4	

29	Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 237	2.3	4
28	Effect of anti-ApoA-I antibody-coating of stents on neointima formation in a rabbit balloon-injury model. <i>PLoS ONE</i> , 2015 , 10, e0122836	3.7	4
27	Sulfated glycosaminoglycans restore glycocalyx barrier properties of cultured endothelial cells in hyperglycemia. <i>FASEB Journal</i> , 2008 , 22, 83-83	0.9	4
26	Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a). <i>Lipids in Health and Disease</i> , 2020 , 19, 91	4.4	3
25	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. <i>Cardiology and Therapy</i> , 2020 , 9, 447-465	2.8	3
24	Targeted proteomics improves cardiovascular risk prediction in secondary prevention <i>European Heart Journal</i> , 2022 ,	9.5	3
23	Lipoprotein(a) Induces Vesicular Cardiovascular Calcification Revealed With Single-Extracellular Vesicle Analysis <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 778919	5.4	3
22	Surmounting the endothelial barrier for delivery of drugs and imaging tracers. <i>Atherosclerosis</i> , 2020 , 315, 93-101	3.1	3
21	Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects. <i>Atherosclerosis</i> , 2020 , 306, 15-21	3.1	3
20	Sympathetic activation by lower body negative pressure decreases kidney perfusion without inducing hypoxia in healthy humans. <i>Clinical Autonomic Research</i> , 2020 , 30, 149-156	4.3	3
19	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , 2018 , 21, 1334-1336	1.2	3
18	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. <i>Heart</i> , 2022 , 108, 61-66	5.1	3
17	Guideline treatment results in regression of atherosclerosis in type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 126-32	3.3	2
16	From evidence to practice: development of web-based Dutch lipid reference values. <i>Netherlands Heart Journal</i> , 2021 , 29, 441-450	2.2	2
15	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003271	5.2	2
14	Dalcetrapib: turning the tide for CETP inhibition?. <i>Lancet, The</i> , 2011 , 378, 1529-30	40	1
13	Letter regarding article by Luo et al, "Adenovirus-mediated expression of beta-adrenergic receptor kinase C-terminus reduces intimal hyperplasia and luminal stenosis of arteriovenous polytetrafluoroethylene grafts in pigs". <i>Circulation</i> , 2005 , 112, e153; author reply e153	16.7	1
12	Cardiovascular risk factors are independently associated with COVID-19 mortality: a prospective cohort study		1

LIST OF PUBLICATIONS

11	PCSK9 Inhibition and Oxidized Phospholipids. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1288-1289	15.1	1
10	Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea <i>Atherosclerosis</i> , 2022 , 344, 7-12	3.1	O
9	Working towards full eradication of lipid-driven cardiovascular risk?. <i>Netherlands Heart Journal</i> , 2021 , 1	2.2	О
8	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. <i>Scientific Reports</i> , 2021 , 11, 4126	4.9	O
7	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2021, 1	2.2	O
6	Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies. <i>Clinical Lipidology</i> , 2013 , 8, 321-328		
5	PS3 - 15. Genetic Variation at the SULF2 Locus Affects Hepatic Postprandial Remnant Clearance in Patients with Type 2 Diabetes Mellitus. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012 , 10, 109-109	O	
4	PS14 - 68. Differential effects of antibiotics on bile acid metabolism, intestinal microbiota composition and insulin resistance in obese humans; a randomised controlled trial. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012 , 10, 147-147	O	
3	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al <i>Heart</i> , 2022 ,	5.1	
2	In vivo glycocalyx degradation induces proteinuria and insulin resistance without affecting atherogenesis in apoE knockout mice on a Western-type diet. <i>FASEB Journal</i> , 2009 , 23, 950.5	0.9	
1	Lipoprotein(a) Measurement in Clinical Practice. <i>JAMA Internal Medicine</i> , 2021 , 181, 1138	11.5	